Elebsiran

DB19018InvestigationalGene Therapies

Elebsiran is under investigation in clinical trial NCT05461170 (SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection.).

Mechanism: Pharmacologically active on HBsAg and External core antigen
Curator reviewed
Code names: ALN-81890 free acid · VIR-2218

Resolves to

Compound

Targets

What you can answer from here — as of October 05, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

9+ReferencesStructured and connected to the statements they support

Which drugs share a target with Elebsiran, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.